Physician profile
Amy Marshall
NPI 1164825493
$3,954.49
in general payments reported to CMS, 2019-2025
40 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,107 · 2022: $420 · 2023: $700 · 2024: $1,132 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,427.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.55 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $496.00 | 2021-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $368.09 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $245.74 | 2021-2025 | Caplyta |
| Novo Nordisk INC | $221.84 | 2023-2025 | Wegovy, Ozempic |
| Lundbeck LLC | $174.52 | 2021-2025 | Rexulti |
| Pfizer INC. | $157.60 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $142.31 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $138.91 | 2021-2024 | Uzedy, Austedo Xr |
| Lilly USA, LLC | $115.16 | 2021-2024 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $99.52 | 2021-2025 | Airsupra |
| Glaxosmithkline, LLC. | $93.89 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $91.41 | 2021-2024 | Trintellix |
| Amgen INC. | $86.21 | 2021-2025 | Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $81.66 | 2024-2025 | Fanapt |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.